TY - JOUR
TI - Cystatin C levels in patients with beta-thalassemia during deferasirox
treatment
AU - Papassotiriou, Ioannis
AU - Margeli, Alexandra
AU - Hantzi, Eugenia and
AU - Delaporta, Polyxeni
AU - Sergounioti, Athanassia
AU - Goussetis, Evgenios
AU - and Ladis, Vassilios
AU - Kattamis, Antonis
JO - BLOOD CELLS MOLECULES AND DISEASES
PY - 2010
VL - 44
TODO - 3
SP - 152-155
PB - ACADEMIC PRESS INC ELSEVIER SCIENCE
SN - 1079-9796
TODO - 10.1016/j.bcmd.2010.01.001
TODO - Thalassemia; Chelation; Renal injury
TODO - Deferasirox (Exjade (R)) is a once-daily, oral iron chelator approved
for the treatment of transfusional iron overload. This study was
conducted to analyze changes in cystatin C concentration, an endogenous
marker of glomerular filtration rate (GFR), in patients with thalassemia
receiving daily deferasirox therapy over a period of at least 9 months.
One hundred and fifty beta-thalassemia patients were treated with
deferasirox at doses of 20-40 mg/kg/day for 9 consecutive months.
Cystatin C concentrations were measured at regular intervals and GFR was
calculated according to the cystatin C-based prediction equation. Plasma
concentrations of NGAL protein and NT-proBNP were also monitored as
indicators of renal function and LVEF, respectively. Serum ferritin
concentration was also measured to assess iron overload. Throughout the
9 months of deferasirox treatment cystatin C concentration remained
stable (p>0.850). The baseline cystatin C mean values were 0.97 +/- 0.27
mg/L and reached a maximum of 1.01 +/- 0.29 mg/L at 4 months of
treatment. No correlation was found between cystatin C and NGAL
concentrations (p>0.674). Cystatin C and NT-proBNP concentrations
correlated positively with a binomial equation (p<0.004), as also did
cystatin C and serum ferritin (p<0.001). These findings suggest that
slight changes of cystatin C during deferasirox treatment may not
reflect renal injury. However hemodynamic signals such as LVEF
alterations and iron mobilization do appear to affect changes in
cystatin C concentration. (C) 2010 Elsevier Inc. All rights reserved.
ER -